摘要
化疗相关性血小板减少症(chemotherapy-induced thrombocytopenia, CIT)仍是目前肿瘤治疗的严重并发症,既往针对CIT的处理主要为输注血小板、使用重组人白介素-11(recombinanthumaninterleukin-11,rhIL-11)及重组人血小板生成素(recombinanthuman thrombopoietin, rhTPO)等,但对一些难治性CIT,效果有限。近年来,新型血小板生成素受体激动剂(thrombopoietin receptor agonists, TPO-RAs)已上市并用于血小板减少症,但尚未批准用于CIT治疗。本文对TPO-RAs类药物在CIT方面已开展的临床研究进行汇总,结果显示罗米司亭、艾曲泊帕、阿伐曲泊帕研究相对较多,但多为小样本或单中心回顾性分析,而芦曲泊帕和海曲泊帕尚缺乏治疗CIT的临床研究。
Chemotherapy-induced thrombocytopenia(CIT)is still a serious complication of tumor therapy.Previous treatments for CIT mainly included platelet infusion and recombinant human interleukin-11(rhIL-11)and recombinant human thrombopoietin(rhTPO),which were not effective in treating refractory CIT.In recent years,new thrombopoietin receptor agonists(TPO-RAs)have been marketed for thrombocytopenia,but have not been approved for the treatment of CIT.In this paper,clinical studies on TPO-RAs in the treatment of CIT were summarized,and the results showed that there were relatively many studies on romiplostim,eltrombopag and avatrombopag,but most of them were small sample or single-center retrospective analysis,while there was a lack of clinical studies on the treatment of CIT with lusutrombopag and hetrombopag.
作者
陈露
陈玥睎
张玉洁
赵晓丽
周寒丽
段方方
孔天东
CHEN Lu;CHEN Yuexi;ZHANG Yujie;ZHAO Xiaoli;ZHOU Hanli;DUAN Fangfang;KONG Tiandong(Department of Oncology,Cancer Hospital of Henan University,the 3rd People's Hospital of Zhengzhou City,Henan Zhengzhou 450000,China;Department of Pharmacy,Liangping District People's Hospital of Chongqing,Chongqing 405200,China)
出处
《现代肿瘤医学》
CAS
2024年第10期1912-1917,共6页
Journal of Modern Oncology
基金
河南省医学科技攻关联合共建项目(编号:2018020746)。
